Mechanisms and disease consequences of nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …
Therapeutic pipeline in nonalcoholic steatohepatitis
R Vuppalanchi, M Noureddin, N Alkhouri… - Nature reviews …, 2021 - nature.com
Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
BA Davison, SA Harrison, G Cotter, N Alkhouri… - Journal of …, 2020 - Elsevier
Background & Aims Liver biopsies are a critical component of pivotal studies in non-
alcoholic steatohepatitis (NASH), constituting inclusion criteria, risk stratification factors and …
alcoholic steatohepatitis (NASH), constituting inclusion criteria, risk stratification factors and …
Breakthroughs in therapies for NASH and remaining challenges
V Ratziu, S Francque, A Sanyal - Journal of hepatology, 2022 - Elsevier
Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …
Nonalcoholic fatty liver disease 2020: the state of the disease
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort
SA Harrison, S Gawrieh, K Roberts, CJ Lisanti… - Journal of …, 2021 - Elsevier
Background & Aims Large prospective studies to establish the prevalence of non-alcoholic
fatty liver disease (NAFLD) and steatohepatitis (NASH), are lacking. We prospectively …
fatty liver disease (NAFLD) and steatohepatitis (NASH), are lacking. We prospectively …
NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances
M Noureddin, A Vipani, C Bresee, T Todo… - Official journal of the …, 2018 - journals.lww.com
OBJECTIVES: Chronic infection with hepatitis C virus (HCV) was previously the leading
indication for liver transplant (LT) in the United States. However, since 2014 the use of direct …
indication for liver transplant (LT) in the United States. However, since 2014 the use of direct …
Nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a disorder characterized by excess accumulation
of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are …
of fat in hepatocytes (nonalcoholic fatty liver (NAFL)); in up to 40% of individuals, there are …
The natural course of non-alcoholic fatty liver disease
L Calzadilla Bertot, LA Adams - International journal of molecular …, 2016 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease
in the world, paralleling the epidemic of obesity and Type 2 diabetes mellitus (T2DM) …
in the world, paralleling the epidemic of obesity and Type 2 diabetes mellitus (T2DM) …
Noninvasive assessment of liver fibrosis in NAFLD
Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of liver-related
morbidity and mortality worldwide, afflicting approximately a billion individuals. NAFLD is a …
morbidity and mortality worldwide, afflicting approximately a billion individuals. NAFLD is a …